Amoy Enters Diagnostic Collaboration with Illumina

Amoy Diagnostics, a Xiamen maker of in vitro diagnostics, will collaborate with Illumina on Next-Generation Sequencing (NGS) Cancer Diagnostics. Amoy will develop and commercialize a series of oncology-related tests based on Illumina’s NGS platforms, including the recently released research-use-only TruSight Tumor 15 as transferred from Illumina to Amoy. The collaboration is said to accelerate the adoption of precision medicine and targeted therapies in China. More details.... Stock Symbol: (NASDAQ: ILMN) Share this with colleagues: // //